📊 HIT Key Takeaways
Is Health In Tech, Inc. (HIT) a Good Investment?
Health In Tech faces significant headwinds with revenue declining 11.3% year-over-year in its insurance services business. While the company maintains a fortress balance sheet with no debt and strong liquidity, thin operating margins (5%) and weak return on equity (7.5%) indicate structural profitability challenges and poor capital efficiency. The marginal improvement in net income appears driven by cost-cutting rather than business expansion, suggesting the company is contracting rather than growing.
Improving profitability and positive free cash flow on a debt-free, highly liquid balance sheet are clear strengths. However, an 11% YoY revenue decline and still-thin operating margins raise questions about the durability of earnings gains. Evidence of top-line stabilization and operating leverage would warrant a more constructive view.
Why Buy Health In Tech, Inc. Stock? HIT Key Strengths
- Pristine balance sheet with zero debt and substantial cash position ($7.7M or 33% of total assets)
- Exceptional liquidity with 3.13x current ratio providing significant financial flexibility
- Healthy gross margin of 62.8% demonstrates strong pricing power in insurance services sector
- Positive free cash flow generation ($3.1M) despite revenue contraction
- Debt-free balance sheet with strong liquidity (3.13x current ratio, $7.67M cash)
- Positive free cash flow (9.4% FCF margin) and improving net income
- High gross margin (62.8%) enabling potential operating leverage
HIT Stock Risks: Health In Tech, Inc. Investment Risks
- Year-over-year revenue decline of 11.3% indicates core business contraction and potential market share loss
- Razor-thin operating margin (5.0%) and net margin (3.8%) provide minimal buffer against cost inflation or disruptions
- Weak return on equity (7.5%) and return on assets (5.5%) signal poor capital allocation and operational efficiency
- Zero insider buying activity in past 90 days suggests lack of management confidence in business prospects
- Double-digit revenue decline suggests potential demand or retention pressure
- Thin operating margin (5%) leaves limited cushion and may reflect one-offs
- Small scale and insurance regulatory exposure could pressure costs and growth
Key Metrics to Watch
- Revenue trend - monitor whether 11.3% YoY decline continues, stabilizes, or reverses
- Operating margin sustainability - critical if revenue continues declining without proportional cost reductions
- Cash position and burn rate - ensure balance sheet strength is not consumed by operating losses
Health In Tech, Inc. (HIT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.13x current ratio provides a solid financial cushion.
HIT Profit Margin, ROE & Profitability Analysis
HIT vs Finance Sector: How Health In Tech, Inc. Compares
How Health In Tech, Inc. compares to Finance sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Health In Tech, Inc. Stock Overvalued? HIT Valuation Analysis 2026
Based on fundamental analysis, Health In Tech, Inc. has mixed fundamental signals relative to the Finance sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Health In Tech, Inc. Balance Sheet: HIT Debt, Cash & Liquidity
HIT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Health In Tech, Inc.'s revenue has grown significantly by 92% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.01 reflects profitable operations.
HIT Revenue Growth, EPS Growth & YoY Performance
HIT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.5M | $100.5K | $0.01 |
| Q2 2025 | $4.9M | $100.5K | $0.01 |
| Q1 2025 | $5.2M | $100.5K | $0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Health In Tech, Inc. Dividends, Buybacks & Capital Allocation
HIT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Health In Tech, Inc. (CIK: 0002019505)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HIT
What is the AI rating for HIT?
Health In Tech, Inc. (HIT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 69% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HIT's key strengths?
Claude: Pristine balance sheet with zero debt and substantial cash position ($7.7M or 33% of total assets). Exceptional liquidity with 3.13x current ratio providing significant financial flexibility. ChatGPT: Debt-free balance sheet with strong liquidity (3.13x current ratio, $7.67M cash). Positive free cash flow (9.4% FCF margin) and improving net income.
What are the risks of investing in HIT?
Claude: Year-over-year revenue decline of 11.3% indicates core business contraction and potential market share loss. Razor-thin operating margin (5.0%) and net margin (3.8%) provide minimal buffer against cost inflation or disruptions. ChatGPT: Double-digit revenue decline suggests potential demand or retention pressure. Thin operating margin (5%) leaves limited cushion and may reflect one-offs.
What is HIT's revenue and growth?
Health In Tech, Inc. reported revenue of $33.3M.
Does HIT pay dividends?
Health In Tech, Inc. does not currently pay dividends.
Where can I find HIT SEC filings?
Official SEC filings for Health In Tech, Inc. (CIK: 0002019505) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HIT's EPS?
Health In Tech, Inc. has a diluted EPS of $0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HIT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Health In Tech, Inc. has a SELL rating with 69% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HIT stock overvalued or undervalued?
Valuation metrics for HIT: ROE of 7.5% (sector avg: 12%), net margin of 3.8% (sector avg: 25%). Compare these metrics with sector averages to assess valuation.
Should I buy HIT stock in 2026?
Our dual AI analysis gives Health In Tech, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HIT's free cash flow?
Health In Tech, Inc.'s operating cash flow is $3.1M, with capital expenditures of N/A. FCF margin is 9.4%.
How does HIT compare to other Finance stocks?
Vs Finance sector averages: Net margin 3.8% (avg: 25%), ROE 7.5% (avg: 12%), current ratio 3.13 (avg: 1.2).